Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Medical Devices

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Dr. Toleikis deserves our Respect and Vote

<< Previous

Bullboard Posts

Next >>

Comment by MustangSalleyon Apr 02, 2021 12:11pm

107 Views

Post# 32932098

RE:RE:Dr. Toleikis deserves our Respect and Vote

Redbaron2211 wrote: Thanks Steadfast agree.

Mustang Sally did you know Frank was one of the founding directors for Angiotech? Just so happens Philip was VP R&D at Angiotech and worked there alongside Frank for a decade and is another example of a company they were involved in that disrupted an industry worth multi billions. Philip and Franks relationship goes way back and predates Ray by decades.

As for getting "robbed" by Canaccord that's a joke look around its all the same in venture capital most companies would kill for a deal like that. If you don't have the stomach for it and you want everything to be rosy then I suggest moving onto some large caps that don't need to raise money.

Red,

Holler was is charge of a fund where Matthews worked . Matthews brought Holler over . Angiotech turned out to be a disaster after their sale and lawsuits to Boston Scientific. I surely hope you don't want the failure of Angiotech. Tolekis was Vice President in Science side , he was not in the board room negotiating anything . Proves my point Tolekis has no business acumen . He has does done a great job getting the company to this point and am sure is a fine person, but you need experienced management that can stick handle through with pharma and licensing deals.

Red I heard a rumour and you should ask Philip or Dominic directly that the group that did the previous pp at higher sp at 30 which was higher than the sp and did not charge any commissions apparently would have done it he raise at much favourable levels . Tolekis apparently did not even take offer sheets from competing firms . That's the rumour .

Red if this is true then you need to open your eyes and see that your investment will not achieve its full potential. How do you not know managements abolity when it comes to do a pharma or iicensing deal that they will not give it away like they did with the financing ?

You have to look at all angles of your investment . All risks and mangement is the biggest risk so far in my opinion .